Business · 02/01/1996Updated: 10/18/2026 · 1 min read
FDA Determines Regulatory Review Period for PREVACID Patent Extension
Summary
The Food and Drug Administration has published a notice determining the regulatory review period for the patent extension of PREVACID, a human drug product, following a submission to the Commissioner of Patents and Trademarks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →